Mayumi Shoji

Urinary podocalyxin levels were associated with urinary albumin levels among patients with diabetes

Mayumi Shoji, K. Kobayashi, Minoru Takemoto et al. · Biomarkers · 2015 · 40 citations

Renal Pathology, Renal Inflammation, Renal Function +19

Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study)

Masaya Koshizaka, Ko Ishikawa, Ryoichi Ishibashi et al. · Diabetes Obesity and Metabolism · 2019 · 39 citations · Full text

Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan

Masaya Koshizaka, Yoshiro Maezawa, Yukari Maeda et al. · Aging · 2020 · 25 citations · Full text

Werner Syndrome, Clinical Symptoms, Clinical Epidemiology +8

Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME‐V study)

Masaya Koshizaka, Ko Ishikawa, Ryoichi Ishibashi et al. · Journal of Diabetes Investigation · 2020 · 24 citations · Full text

Serum podocalyxin levels correlate with carotid intima media thickness, implicating its role as a novel biomarker for atherosclerosis

Mayumi Shoji, Minoru Takemoto, Kazuki Kobayashi et al. · Scientific Reports · 2018 · 23 citations · Full text